TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$7.72
0.13 (1.71%)
▲
5d:
+7.97%
30d:
+16.27%
90d:
-42.73%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $7.72, which is considered extended relative to its 30-day fair value range of $6.41 to $7.38.
Technical Outlook: Technically, TRDA is in a strong downtrend. Immediate support is located at $6.76, while resistance sits at $8.10.
Market Sentiment: TRDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.75 (+142.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TRDA is in a strong downtrend. Immediate support is located at $6.76, while resistance sits at $8.10.
Market Sentiment: TRDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.75 (+142.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.41 -
$7.38
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 142.9% below Wall St target ($18.75)
Trading Range Analysis
30-Day Trading Range
$6.41 -
$7.38
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.76
Resistance Level
$8.10
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.37
Wall Street Target
$18.75
(+142.9%)
Revenue Growth (YoY)
-95.7%
Share & Embed Analysis
Last updated: July 04, 2026 6:16 PM ET
Data refreshes hourly during market hours. Next update: 7:16 PM
Data refreshes hourly during market hours. Next update: 7:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |